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Orexin system is expressed 
in avian liver and regulates hepatic 
lipogenesis via ERK1/2 activation
E. S. Greene1, M. Zampiga2, F. Sirri2, T. Ohkubo3 & Sami Dridi1*
Orexins are originally characterized as orexigenic hypothalamic neuropeptides in mammals. 
Subsequent studies found orexin to be expressed and perform pleiotropic functions in multiple 
tissues in mammals. In avian (non-mammalian) species, however, orexin seemed to not affect 
feeding behavior and its physiological roles are poorly understood. Here, we provide evidence that 
orexin and its related receptors are expressed in chicken hepatocytes. Double immunofluorescence 
staining showed that orexin is localized in the ER, Golgi, and in the lysosomes in LMH cells. 
Brefeldin A treatment reduced orexin levels in the culture media, but increased it in the cell lysates. 
Administration of recombinant orexins upregulated the expression of orexin system in the liver of 
9-day old chicks, but did not affect feed intake. Recombinant orexins increased fatty acid synthase 
(FASN) protein levels in chicken liver, activated acetyl-CoA carboxylase (ACCα), and increased 
FASN, ATP citrate lyase(ACLY), and malic enzyme (ME) protein expression in LMH cells. Blockade 
ERK1/2 activation by PD98059 attenuated these stimulating effects of orexin on lipogenic factors. 
Overexpression of ERK1/2 increased the expression of lipogenic genes, and orexin treatment induced 
the phosphorylated levels of ERK1/2Thr202/Tyr204, but not that of p38 Thr180/Tyr182 or JNK1/2 Thr183/Tyr185 in 
chicken liver and LMH cells. Taken together, this is the first report evidencing that orexin is expressed 
and secreted from chicken hepatocytes, and that orexin induced hepatic lipogenesis via activation of 
ERK1/2 signaling pathway.
Orexin A and  B1 (also known as hypocretins 1 and  22) are 33-amino acid (ORX-A) and 28-amino acid (ORX-B) 
peptides derived from proteolytic cleavage of a single precursor, prepro-orexin, and were originally discovered 
to be produced by several feeding-related hypothalamic nuclei in rodents and  humans1,2. More recently, orexins 
and their cognate receptors have been found to be expressed in several mammalian peripheral tissues, includ-
ing the gastrointestinal tract, pancreas, adrenals, kidney, adipose tissue, and the reproductive tract (for review 
 see3), suggesting potential pleiotropic functions and involvement in multiple versatile physiological processes 
(for review  see4).
The physiological effects of orexin (ORX) are mediated by two G-protein coupled receptors, orexin receptor 
1 (ORXR1) and orexin receptor 2 (ORXR2). Originally identified as regulators of feeding  behavior5, orexins are 
also known to control sleep–wake  cycle6–8, energy balance and glucose  homeostasis9,10, autonomic  function11,12, 
and as a modulator of the stress  response13,14. In adipocytes, orexin has been shown to decrease  lipolysis15 and 
increase lipid  accumulation16, hinting at effects on adipogenesis and lipogenesis.
In avian (non-mammalian) species, although prepro-orexin sequence is highly  conserved17, and avian orexin 
system was found in the brain, testis, ovary, stomach, and  intestine18,19, little is known about its physiological 
roles. Recently, we have shown the presence of ORX and its receptors, ORXR1 and ORXR2, in the  muscle20 of 
avian species and demonstrated its role in modulating energy metabolism and mitochondrial function.
As orexin has been shown to play a key role in lipid metabolism in rodents, and as fat accumulation and 
liver hemorrhagic syndrome are a source of substantial burden and cost to poultry, we undertook this study 
to determine the role of orexin in avian lipid metabolism. Since the liver is the primary site for de novo fatty 
acid synthesis in  chicken21, we hypothesized that orexin may be produced by the hepatocytes and may regulate 
lipogenesis. Our data showed that orexin system is expressed in chicken liver and avian hepatocyte cell lines 
and that orexin administration modulate the expression of lipogenic genes. The effect of orexin on avian hepatic 
lipogenesis seems to be mediated via extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathways.
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Materials and methods
Animals. Day-old male broilers (Cobb 500, Cobb-Vantress, Siloam Springs, AR) were divided into 3 weight-
matched groups (39.75 ± 0.26 g), reared for 8 days, and have ad libitum access to clean water and feed (4.090 
Mcal ME  kg−1 and 22% CP). The ambient temperature was reduced gradually (1 °C every 2 days) from 32 to 
29 °C, and the relative humidity was maintained at 55 ± 2%. Feed and water intake were recorded hourly. On day 
9, birds received an intraperitoneal (i.p.) injection of recombinant human orexin-A or -B (rORX-A or -B; Alpha 
Diagnostic International, San Antonio, TX, 100 ng/100 g BW, n = 12). The control group received a saline solu-
tion. Three hours after administration, birds were euthanized by cervical dislocation. Blood was collected and 
250 µL added to Trizol LS reagent (Life Technologies, Carlsbad, CA) for mRNA extraction. Liver samples were 
immediately collected, snap frozen in liquid nitrogen and stored at − 80 °C for further analysis. The present study 
was conducted in accordance with the recommendations in the guide for the care and use of laboratory animals 
of the National Institutes of Health and the protocols were approved by the University of Arkansas Institutional 
Animal Care and Use Committee under protocol # 16084.
Leghorn Male Hepatoma (LMH) cell culture and treatments. LMH cells (ATCC CRL-2117) or 
spontaneously immortalized chicken embryonic hepatocytes  (siCEH22) were grown on 0.1% gelatin-coated cul-
ture dishes in Waymouth’s media (Life Technologies, Carlsbad, CA), supplemented with 10% FBS (Life Tech-
nologies, Carlsbad, CA), and 1% penicillin–streptomycin (BioBasic, Amherst, NY) at 37 °C, in a humidified 
atmosphere of 5%  CO2 and 95% air. At ~ 80% confluence, cells were synchronized with serum-free media over-
night and treated with different doses (0, 10, and 100 nM) of recombinant human ORX-A or ORX-B (Alpha 
Diagnostic International, San Antonio, TX) for 24 h. The dose of orexins was selected based on pilot and previ-
ous  studies16,20,23,24. 30 min before orexin treatments, LMH cells were incubated with brefeldin A (0.3 µg/mL) for 
24 h and lysates and medium were subjected to immunoblot analyses. All culture experiments were performed 
with cells from passages 10–15 and repeated at least twice.
Transient overexpression and inhibition of ERK1/2. At 50–60% confluence, LMH cells were pre-
treated with PD98059 (10 µM, ThermoFisher Scientific, Waltham, MA) 30 min before orexin administration. 
Cells were transiently transfected with pEGFP-ERK1, pEGFP-ERK2, and pEGFP empty vector (mock) using 
Lipofectamine 2000 (ThermoFisher Scientific, Waltham, MA) according to the manufacturer’s instructions. Six 
to eight hours post transfection, complete medium was added and cells were maintained for additional 16 h and 
were processed for immunoblotting.
RNA isolation and quantitative real-time PCR. For chicken liver and cell lysates, total RNA was 
extracted using Trizol reagent (Life Technologies, Carlsbad, CA) according to the manufacturer’s instructions, 
and concentration and quality were determined by using the Take3 micro-volume plate and the Synergy HT 
multimode microplate reader (BioTek, Winooski, VT). The ratio of absorbance (A260/280) as well as agarose gel 
electrophoresis were used to assess RNA integrity and quality. RNA was reverse transcribed using qScript cDNA 
Sythesis Supermix (Quanta Biosciences, Gaithersburg, MD), and amplified by qPCR (Applied Biosystems 7500 
Real Time System) with SYBR green master mix (Life Technologies, Carlsbad, CA) as previously  described25–27. 
Relative expression of the target genes was determined using the  2−ΔΔCT method, with normalization to r18S 
 expression28. Oligonucleotide primers specific for chicken are summarized in Table 1.
Conventional PCR. Total RNA was extracted and reverse transcribed as described above. Fragments of 
ORX, ORXR1/2, and r18S were amplified by PCR using specific  primers20. PCR was performed using 43 μL of 
Platinum PCR SuperMix (Life Technologies, Carlsbad, CA), 5 μL of cDNA, and 1μL of each forward and reverse 
primers. Thermal cycling parameters for ORX and ORXR1/2 were: 94 °C for 4 min, followed by 39 cycles of 94 °C 
for 30 s, 50 °C for 30 s, 72 °C for 1 min, with a final extension at 72 °C for 10 min. For r18S, the temperatures 
were the same, but the annealing and elongation steps were each held for 1 min. Fragments were separated on a 
1% agarose gel electrophoresis and images captured using the FluorChem M MultiFluor System (ProteinSimple, 
San Jose, CA ).
Western blot analysis. Liver tissue and cells were homogenized in lysis buffer (10 mM Tris Base, pH 7.4, 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% Triton X-100, 0.5% NP-40, protease and phosphatase inhibi-
tors). Protein concentrations were determined using a Bradford assay kit (Bio-Rad, Hercules, CA) and a Synergy 
HT multimode microplate reader (BioTek, Winooski, VT). Proteins (80 μg liver tissue, 40 μg cell lysate) were 
run on 4–12% gradient Bis–Tris gels (Life Technologies, Carlsbad, CA), and transferred to PVDF membranes. 
The membranes were blocked with 5% non-fat milk in TBS-T for 1 h at room temperature, then incubated with 
primary antibodies (1:500–1:1000 dilution) overnight at 4 °C. Secondary antibodies (1:5000) were diluted in 
5% milk in TBS-T and membranes were incubated at room temperature for 1 h. Primary antibodies used were: 
rabbit anti-ORX, rabbit anti-ORXR1, rabbit anti-ORXR2 (Interchim, France), rabbit anti-phospho-ACCαSer79, 
rabbit anti-ACCα, rabbit anti-FASN, rabbit anti-phospho-ERK1/2Thr202/Tyr204, rabbit anti-ERK1/2, rabbit anti-
phospho-SAPK/JNKThr183/Tyr185, rabbit anti-SAPK/JNK, rabbit anti-phospho-P38  MAPKThr180/Tyr182, rabbit anti-
P38 MAPK (Cell Signaling Danvers, MA), and rabbit anti-nucleoline (Santa Cruz Biotechnology, Dallas, TX ). 
To assess protein loading, the expression of the housekeeping GAPDH protein was determined using rabbit anti-
GAPDH antibody (Santa Cruz Biotechnology, Dallas, TX). The signal was visualized by chemiluminescence 
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Immunofluorescence. Immunofluorescence was performed as previously  described25. Briefly, cells were 
grown in chamber slides and fixed with methanol for 10 min at − 20 °C, then permeabilized with Triton-X 100. 
Cells were blocked with serum-free protein block (Dako, Carpinteria, CA) for 1 h at room temperature, then 
incubated with anti-ORX, anti-ORXR1, anti-ORXR2, anti-phospho-ACC Ser79 or anti-phospho-ERK1/2Thr202/
Tyr204 (1:200, in Antibody Diluent, Dako, Carpinteria, CA, overnight at 4 °C) for mono-staining or a combination 
of anti-ORX with anti-ERGIC53 or anti-TGN38 for double-labeling immunofluorescence. For ER or lysosome 
co-labeling with ORX, cells were incubated with 100 nM of ER-Tracker or Lyso-Tracker (ThermoFisher Scien-
tific, Waltham, MA) for 15–30 min before fixation and then proceeded as mentioned above. Signal was visual-
ized with DyLight 488-conjugated secondary antibody (Thermo Fisher Scientific, Grand Island, NY). Slides were 
cover slipped with Vectashield with DAPI (Vector Laboratories, Burlingame, CA), and images were obtained 
and analyzed using Zeiss Imager M2 and AxioVision software (Carl Zeiss Microscopy).
Statistical analysis. Data were analyzed by one-way ANOVA. Significant differences among individual 
group means were determined by Student–Newman–Keul’s multiple range test with GraphPad Prism v. 6.00 (La 
Jolla, CA). Significance was set at α = 0.05. All data are represented as means ± SEM.
Table 1.  Oligonucleotide qPCR primers. a Accession number refer to Genbank (NCBI).
Gene Accession  numbera Primer sequence Orientation Product size (bp)
ORX AB056748
CCA GGA GCA CGC TGA GAA G For
67
CCC ATC TCA GTA AAA GCT CTT TGC Rev
ORXR1 NM_001024584.1
TGC GCT ACC TCT GGA AGG A For
58
GCG ATC AGC GCC CATTC Rev
ORXR2 XM_004945362
AAG TGC TGA AGC AAC CAT TGC For
61
AAG TGC TGA AGC AAC CAT TGC Rev
ACC NM_205505.1
CAG GTA TCG CAT CAC TAT AGG TAA CAA For
74
GTG AGC GCA GAA TAG AAG GATCA Rev
FAS NM_205155.2
ACT GTG GGC TCC AAA TCT TCA For
70
CAA GGA GCC ATC GTG TAA AGC Rev
ME NM_204303.1
AGA TGA AGC TGT CAA AAG GAT ATG For
62
CAC GCC CCT TCA CTA TCG A Rev
ACLY NM_001030540.1
CTT TTA AGG GCA TTG TTA GAG CAA T For
65
CCT CAC CTC GTG CTC TTT CAG Rev
SCD-1 NM_204890.1
CAA TGC CAC CTG GCT AGT GA For
52
CGG CCG ATT GCC AAAC Rev
SREBP-1 NM_204126.2
CAT CCA TCA ACG ACA AGA TCGT For
82
CTC AGG ATC GCC GAC TTG TT Rev
SREBP-2 XM_015289037.2
GCC TCT GAT TCG GGA TCA CA For
63
GCT TCC TGG CTC TGA ATC AATG Rev
PPARα NM_001001464.1
CAA ACC AAC CAT CCT GAC GAT For
64
GGA GGT CAG CCA TTT TTT GGA Rev
PPARγ NM_001001460.1
CAC TGC AGG AAC AGA ACA AAGAA For
67
TCC ACA GAG CGA AAC TGA CATC Rev
INSIG1
TGG CGC TGG TGC TGAAC For
63
TGA CCT CGT CGG GAA ACA G Rev
INSIG2 NM_001305465.1
CAG CGC TAA AGT GGA TTT TGC For
65
CAA TTG ACA GGG CTG CTA ACG Rev
SCAP XM_025147369.1
TGG CCC AGA GAC TCA TCA TG For
67
GCA GGA TCC GTA TAA ACC AGGAT Rev
ERK NM_204150.1
CGG ACC ATG ATC ACA CAG GAT For
63
CAG GAG CCC TGT ACC AAC GT Rev
JNK NM_205095.1
GCC GAT GAT CAG CCA GGA T For
62
GGC CCA ATG GAA GCA AGA G Rev
p38 XM_419263.5
AGC TGG AGA TTG AGG AAT GGAA For
62
CGG TGG CAC AAA GCT GAT TA Rev
18s AF173612
TCC CCT CCC GTT ACT TGG AT For
60
GCG CTC GTC GGC ATGTA Rev
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Results
Orexin system is expressed in avian liver cells. By using immunoblot with antibody that cross-reacts 
with chicken orexin  system20, we amplified a strong signal of orexin with only one band at the predicted size 
(16 kDa) in chicken liver as well as in LMH and siCEH cells (Fig. 1a). However, we observed two bands with 
molecular weight of 16 and 230 kDa in the hypothalamus (positive control, Fig. 1a). We amplified also a strong 
signal of orexin receptors in chicken hepatocytes (Fig. 1a). Orexin protein levels are significantly higher in the 
chicken liver compared to the hypothalamus (Fig. 1b), however its mRNA abundance are significantly lower 
(Fig. 1d). The expression (mRNA and protein) of orexin receptor (ORXR2) did not differ between the chicken 
liver and the hypothalamus (Fig. 1c,e,f). Immunofluorescence staining showed a strong reactivity of ORX and 
its related receptors (ORXR1 and ORXR2) in the cytoplasm of LMH cells (Fig. 1g). The predominant cytoplas-
mic localization of chicken orexin system was further confirmed by cell fractionation and Western blot analysis 
(Fig. 1h). To further determine the sub-cellular localization and distribution of orexin in LMH cells, double-
labeling immunofluorescence was performed. Chicken orexin was stained in combination with the well charac-
terized ER fluorescent tracking dye, ER-Tracker, and shows to be predominantly localized in the ER of LMH cell 
line (yellow arrows, Fig. 2a–c). Immunofluorescence localization of Golgi markers suggests that chicken orexin 
is also localized, in the cis side (co-staining with ERGIC 53), and in the trans side of Golgi complex (co-staining 
with TGN38) in LMH cells (yellow arrows, Fig.  2d–i). The co-staining of chicken orexin with the lysosome 
tracking dye, lyso-Tracker deep red, suggests that chicken orexin is also localized in the lysosome (yellow arrows, 
Fig. 2j–l). Analysis of conditioned medium by Western blot showed specific secretion of orexin in LMH cells at 
48 h (Fig. 2m–o), and treatment of cells with brefeldin A (BFA, 0.3 µg/mL), partially but significantly blocked 
orexin secretion which is demonstrated by a ~ 26% decrease of ORX levels in the medium and a significant accu-
mulation in cell lysate (Fig. 2p,q).
Orexin modulates its own expression in chicken liver and LMH cells. Intraperitoneal (IP) admin-
istration of recombinant orexin B, but not orexin A, significantly increases ORX mRNA abundances in chick 
blood (Fig. 3a). Neither recombinant orexin A nor B affect body weight (BW), feed intake (FI), or water con-
sumption (WI) in chicks (Fig. 3b–d). Hepatic ORX and ORXR2 protein levels were significantly increased fol-
lowing administration of recombinant orexins (ORX-A and ORX-B) (Fig. 3e,f). Although, neither hepatic ORX 
nor ORXR1 mRNA abundances were affected by recombinant orexin treatments, hepatic ORXR2 gene expres-
sion was significantly down regulated by rORX-B administration (Fig. 3g). In LMH cells, treatment for 24 h with 
100 nM of rORX-A significantly down regulated prepro-ORX and ORXR1, but increased ORXR2 protein levels 
(Fig. 3h,i). Low dose of rORX-A increased both ORXR1 and ORXR2 protein expression and upregulated ORX 
and ORXR1 gene expression in LMH cells (Fig. 3h–j). Treatment with rORX-B at high dose, however, increased 
ORX and ORXR1 protein levels and down regulated ORX mRNA abundance in LMH cells (Fig. 3k–m). Recom-
binant ORX-B at low dose (10 nM) induced both ORXR1 and ORXR2 protein expression and only ORXR2 
mRNA levels in LMH cells (Fig. 3k–m).
Orexin regulates lipogenic program in chicken hepatocytes. Administration of recombinant orexin 
A or B significantly decreased phosphorylated ACCαSer79 and increased FASN protein levels, the rate-limiting 
enzymes involved in lipogenesis (Fig. 4a–c) and down regulated the expression of ACCα, FASN, ACLY, and SCD-
1 genes in chicken liver (Fig. 4d,e). Recombinant orexin A significantly upregulated the hepatic expression of the 
transcription factors SREBP-1 and SREBP-2 (Fig. 4f), however recombinant orexin B significantly increased only 
SREBP-2 mRNA abundances (Fig. 4g). In vitro studies using LMH cells showed that both recombinant orexins 
at low and high dose significantly reduced the phosphorylated levels of ACCα at Ser79 site (Fig. 5a–c). As shown 
in Fig. 5d, immunofluorescence staining confirmed the reduced levels of ACCα phosphorylation in LMH cells 
following recombinant orexin B treatment. Orexin treatments also significantly increased the protein levels of 
FASN, ACLY, and ME in LMH cells (Fig. 5a–c). At transcriptional levels, recombinant orexin A down regulated 
ACCα and upregulated ME and SCD-1 gene expression in LMH cells (Fig. 5e). Administration of high dose of 
recombinant orexin B significantly increased the mRNA levels of ACCα, FASN, ACLY, and ME (Fig. 5f). These 
changes were accompanied with a significant down regulation of SREBP-1 and an upregulation of SREBP-2, 
INSIG-1, and PPARγ with recombinant orexin A treatment, and an upregulation of SREBP-1 and a down regula-
tion of INSIG-1 and SCAP with the administration of recombinant orexin B (Fig. 5g, h).
Orexin B modulates hepatic lipogenesis via ERK1/2 pathway. Treatment with both doses of recom-
binant orexin B specifically and significantly induced phospho-ERK1/2Thr202/Tyr204 but not that of phospho-p38 
Thr180/Tyr182 or phospho-JNK1/2 Thr183/Tyr185 in LMH cells (Fig. 6a–c). High dose of recombinant orexin B signifi-
cantly up regulated the expression of ERK1, ERK2, JNK, and P38 genes in LMH cells (Fig. 6e). Administration of 
recombinant orexin A, however, did not elicit any changes to ERK1/2, p38, or JNK1/2 at both mRNA and protein 
levels (Fig. 6a,b,d). Overexpression of ERK1 or ERK2 (Fig. 6f,g) significantly decreased phospho-ACCαSer79 and 
increased ME protein levels in LMH cells (Fig. 6f,g). ERK1 and ERK2 overexpression significantly upregulated 
the expression of ACCα, FASN, ACLY, and SREBP-1 (Fig. 6h). Pharmacological inhibition of ERK1/2 activa-
tion by PD98059 (Fig. 7a,b) blockaded the effects of recombinant orexin B on lipogenic program in LMH cells 
(increased phospho-ACCαSer79 and decreased FASN protein levels and down regulated ACCα and ME mRNA 
abundances) (Fig. 7c–e). Recombinant orexins specifically activated ERK1/2 at Thr202/Tyr204 site, but not P38 
or JNK, in chicken liver (Fig. 8a–c). Recombinant orexins did not affect the hepatic expression of ERK1/2, P38, 
or JNK1/2 genes (Fig. 8d,e).
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Figure 1.  Orexin and its related receptors are expressed in chicken liver and hepatocyte cells. (a–c) Total 
proteins were isolated from chicken hypothalamus (positive control), liver, LMH, and siCEH cells and subjected 
to Western blot using anti-orexin and anti-ORXR2 antibodies and data are expressed as ratios to GAPDH. (d–f) 
Total RNA was reverse transcribed and subjected to RT-qPCR as described in the “Materials and methods” with 
chicken hypothalamus served as a calibrator, and relative expression was determined by  2−ΔΔCt  method28. (g) 
Distribution of intracellular orexin system was determined by immunofluorescence staining with secondary 
antibody conjugated with AlexaFluor 488 (green) and DAPI (blue). (h) Proteins of cellular components 
(nucleus, cytoplasmic, and total) were obtained by cell fractionation and submitted to Western blot analysis 
as described above. Nucleolin was used as a positive control for the nuclear fraction. *Significant difference 
from the hypothalamus, P < 0.05. Cyto cytoplasmic, LMH leghorn male hepatoma cells, Nuc nuclear, siCEH 
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Figure 2.  Subcellular localization and secretion of orexin by LMH cells. Chicken orexin was stained in 
combination with well characterized markers of the ER (ER-Tracker, a–c), cis (ERGIC53, d–f) and trans 
side (TGN38, g–i) of the Golgi complex, and the lysosome (lyso-Tracker, j–l). Yellow arrows showed the 
co-localization of chicken orexin (ORX) with target organelle-markers. Cell monolayers were incubated in 
serum-free media for indicated time periods, and collected media and cell lysates were subject to Western 
blot for orexin protein expression (m–o). Cells were pretreated with brefeldin A and collected media and cell 
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Figure 3.  Orexin regulates its own system in chicken liver and LMH cells. Intraperitoneal injection of human recombinant orexins (A 
and B, 100 ng/100 g BW) affects blood orexin mRNA levels (a), BW (b), FI (c), WI (d), and liver expression of orexin and ORXR2 at 
protein (e,f) and mRNA levels (g). Orexin treatment affects orexin, ORXR1, and ORXR2 at protein (h,i,k,l) and mRNA levels (j,m) in 
LMH cells. mRNA abundances and protein levels were determined by qPCR and Western blot, respectively as described in “Materials 
and methods”. Data are presented as mean ± SEM (n = 12 birds/group). *Significant difference from controls, P < 0.05. Western blot 
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Discussion
Orexin A and B neuropeptides have attracted much recent attention due to their pleiotropic physiological func-
tions. They were initially characterized in the brain and first emerged as appetite inducers and regulators of 
Figure 4.  Orexin regulates lipogenic program in chicken liver. Intraperitoneal administration of human 
recombinant orexins affects lipogenic factors (ACC, FASN, ACLY, ME, SCD-1) and their transcription factors. 
Protein expression (a–c) was determined by Western blot and gene expression (d–g) was measured by qPCR. 
Data are presented as mean ± SEM (n = 12 birds/group). *Indicates significant difference from controls at 
P < 0.05. ACC acetyl-CoA carboxylase, ACLY ATP citrate lyase, FASN fatty acid synthase, INSIG-2 insulin-
induced gene 2, ME malic enzyme, PPAR peroxisome proliferator-activated receptor, SCD-1 stearoyl-CoA 
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Figure 5.  Orexin regulates lipogenic program in LMH cell line. Orexin treatments affects lipogenic factors 
(ACC, FASN, ACLY, ME, SCD-1) and their transcription factors. Protein expression (a–c) was determined 
by Western blot and gene expression (e–h) was measured by qPCR. Phosphorylated levels of ACC was also 
assessed by immunofluorescence staining (d). Data are presented as mean ± SEM (n = 6/group). *Indicates 
significant difference from controls at P < 0.05. ACC acetyl-CoA carboxylase, ACLY ATP citrate lyase, FASN 
fatty acid synthase, INSIG-2 insulin-induced gene 2, ME malic enzyme, PPAR peroxisome proliferator-activated 
receptor, SCD-1 stearoyl-CoA desaturase-1, SREBP-1/2 sterol regulatory element-binding protein 1/2. Full-
length blots/gels are presented in Supplementary Fig. S1.
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Figure 6.  Orexin activates ERK1/2 signaling cascade in LMH cells. Orexin administration increased 
p-ERK1/2Thr202/Tyr204 levels, but not that of p-P38Thr180/Tyr182 or p-JNK1/2Thr183/Tyr185 in LMH cells as demonstrated 
by Western blot analyses (a–c). The relative expression of MAPK genes was measured by qPCR (d,e). 
Overexpression of ERK1 or ERK2 increased p-ERK1/2Thr202/Tyr204, activated ACC and increased ME protein 
levels (f,g) as well as the mRNA abundances of ACC, FASN, ME, ACLY and SREBP-1 (h). Data are presented 
as mean ± SEM (n = 6/group). *Indicates significant difference from controls at P < 0.05. ACC acetyl-CoA 
carboxylase, ACLY ATP citrate lyase, ERK extracellular signal-regulated kinase, FASN fatty acid synthase, 
JNK c-Jun N-terminal kinase, ME malic enzyme, P38 P38 mitogen-activated protein kinase, SREBP-1 sterol 
regulatory element-binding protein 1. Full-length blots/gels are presented in Supplementary Fig. S1.
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feeding behaviors and energy homeostasis in  mammals4. Numerous studies showed that orexins and their two 
known G-protein-coupled receptors are expressed in many peripheral tissues and play crucial roles in sleep and 
wakefulness  cycle6–8, energy  metabolism9,10, stress  response13,14, and glucose and lipid  metabolism23,29 in mam-
malian species. Although orexins were found to be expressed not only in the hypothalamus of chickens (non-
mammalian species)17, but also in gastrointestinal  tract18, reproductive  organs19, and  muscle20, their functions are 
still not well defined. The objective of the current study was to investigate the potential role of the orexin system 
in avian hepatic lipid metabolism. As in humans, chicken liver is the primary site of de novo fatty acid  synthesis21. 
Figure 7.  Blockade ERK1/2 activation prevents orexin-induced lipogenesis in LMH cells. Pharmacological 
inhibition of ERK1/2 using PD98059, as confirmed by Western blot (a) and immunofluorescence (b), blocked 
the effect of orexin on the expression lipgenic factors (c–e). Data are presented as mean ± SEM (n = 6/group). 
*Indicates significant difference from the untreated group (control) at P < 0.05. ACC acetyl-CoA carboxylase, 
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Additionally, commercial broiler (meat-type) chicken are often hyperphagic and prone to fat  accumulation30. 
Since obesity is a worldwide epidemic, these peculiarities make the chicken a high relevant animal model for 
further understanding hepatic lipid metabolism in both poultry and humans.
By using different techniques (qPCR, immunoblot, and immunofluorescence staining), we first demon-
strated that orexin and its related receptors ORXR1 and ORXR2 are expressed in chicken liver and LMH cells. 
Cell fractionation showed that orexin system is mainly localized in the cytoplasm. Further subcellular analyses 
by double-labeling immunofluorescence indicated that orexin is localized in ER, Golgi apparatus, and in the 
lysosome. Although the intracellular distribution of orexin system has not been reported previously, several 
studies showed that orexin system couples to  Ca2+ influx and  release31–33. As the ER plays a key role in calcium 
homeostasis and  storage34, together these studies suggested that orexin might be localized in the ER which is 
supported by COMPARTMENTS, the subcellular localization database (https ://compa rtmen ts.jense nlab.org). 
Additionally, orexin contains an ER signal  sequence35. The presence of orexin in ER and Golgi as well as in the 
culture media indicated that orexin is secreted from chicken hepatocytes. This is confirmed by brefeldin A treat-
ment, the potent inhibitor of secretion via disruption and disassembly of the Golgi leading to the accumulation 
of orexin in the cell  lysate36. The localization of orexin in the lysosome suggested that orexin might be involved 
in autophagosome-lysosome fusion process and autophagy  machinery37,38.
Figure 8.  Orexins activate ERK1/2 signaling cascade in chicken liver. Intraperitoneal administration of 
recombinant orexins increased p-ERK1/2Thr202/Tyr204 levels, but not that of p-P38Thr180/Tyr182 or p-JNK1/2Thr183/
Tyr185 in chicken liver as demonstrated by Western blot analyses (a–c). The relative expression of MAPK genes 
was measured by qPCR (d,e). Data are presented as mean ± SEM (n = 12 birds/group). *Indicates significant 
difference from controls at P < 0.05; ERK extracellular signal-regulated kinase, JNK c-Jun N-terminal kinase, P38 
P38 mitogen-activated. Full-length blots/gels are presented in Supplementary Fig. S1.
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Although both recombinant orexins upregulated the hepatic orexin system in vivo, rORX-A and rORX-B 
had differential effects on ORX protein expression in LMH cells. These differences might be due to structural 
differences between ORX-A and -B (ORX-A contains two disulfide bonds as compared to one in ORX-B) and/
or binding affinity of the orexins to their  receptors39. In fact, mammalian ORXR1 preferentially binds ORX-A, 
while ORXR2 has similar affinity for both ORX-A and -B1. Additionally, heterodimerization with other G-protein 
coupled receptors is known to affect orexin receptor  activation40. Determination of the crystal structure of the 
chicken orexin receptors as well as their ligand-binding properties may help to further elucidate the differen-
tial actions of orexin-A and -B41. Similarly, changes in mRNA and protein expression of orexin system are not 
concomitant. For instance, orexin administration upregulated ORX and ORXR2 protein levels without affecting 
their mRNA abundances. This lack of correlation between mRNA and protein levels is not  surprising42 and it 
might be explained by the involvement of varied post-transcriptional and post-translational mechanisms and/
or protein and RNA half-  lives43. The hepatic expression and secretion of orexin system as well as its ability to 
regulate its own system suggested that orexin might have autocrine, paracrine, and/or endocrine  function44.
Though originally identified as a regulator of feeding behavior in mammals, orexin does not appear to have 
this effect in chicken in our study and that of  others45, leading to questions regarding its role in avian physiol-
ogy. Here we showed for the first time that orexin administration in vivo increased hepatic FASN protein levels, 
which is a rate-limiting enzyme of fatty acid synthesis via catalyzing the synthesis of palmitate from acetyl-CoA 
and malonyl-CoA into long-chain saturated fatty  acids46. In support of the in vivo data, orexin treatments also 
induced the expression of key lipogenic proteins including FASN, ACLY and ME in LMH cells. Reduction of its 
phosphorylated levels indicated the activation of ACCα, which constitutes a key control point in the synthesis of 
long-chain fatty acids through catalyzing the carboxylation of acetyl-CoA in the generation of malonyl-CoA47. 
In line with our results, previous studies have shown that orexin stimulated lipid accumulation in primary rat 
adipocytes and 3T3-L1  cells23. Pruszynska-Oszmalek and co-workers reported that orexin stimulated prolifera-
tion and differentiation of porcine preadipocytes and regulated lipid  metabolism29,48. It is noteworthy to mention 
that, as for orexin system and for the same reasons mentioned above, mRNA and protein levels of lipogenic 
factors were not correlated. Interestingly, in vivo administration of rORX-A up-regulated both hepatic SREBP-1 
and SREBP-2, however rORX-B induced only SREBP-2 gene expression. In LMH cells, however, rORX-A down-
regulated SREBP-1 and up-regulated SREBP-2 and INSIG-1 gene expression, and rORX-B increased SREBP-1 
and decreased INSIG-1 and SCAP mRNA abundances. Although the mechanisms contributing to the differential 
regulation of transcription factors SREBP-1/2 between rORX-A and rORX-B on one hand, and between in vivo 
and in vitro studies on the other hands, are not known, it is possible that other transcription factors might be 
involved. For instance, the up-regulation of PPARγ in LMH cells following rORX-A treatment might compen-
sate for the down-regulation of SREBP-1. It has been shown that PPARγ is one of the downstream mediators of 
orexin’s  action23. The consistent increase in SREBP-2 mRNA levels following rORX-A administration in both 
chicken liver and LMH cells indicated that at least rORX-A regulate cholesterol  metabolism49.
Orexin has been shown to activate various signaling  pathways4,50 and lipogenic enzymes have been reported 
to be regulated by diverse  mechanisms51. In attempt to define the downstream mediators of orexin action on 
avian hepatic lipogenesis, we sought to determine the involvement of MAPK cascades. Orexin administration 
led to ERK1/2 phosphorylation at Thr202/Tyr204 residues, but not that of P38 and JNK1/2 in both chicken 
liver and LMH cells. Overexpression and activation of ERK1 or ERK2 up-regulated the expression of lipogenic 
genes (ACCα, FASN, ME, and ACLY), and their transcription factor SREBP-1, increased ME protein levels, and 
activated ACCα as demonstrated by its dephosphorylation. Pharmacological inhibition of ERK1/2 activation 
by PD98059 prevents orexin-induced lipogenesis. Orexin has been shown to activate ERK1/2 in multiple cell 
types and species, including CHO  cells52, SGC-7901 gastric cancer  cells53, H295R adrenocortical  cells54, neuro-
2a  cells55, and 3T3-L1  cells56. ERK1/2 signaling pathway is involved in a wide variety of cellular processes. Roth 
and co-workers57 have shown that ERK1/2 regulated the key lipogenic transcription factor SREBP-1 and several 
lines of evidence have implied a link between ERK1/2 and lipid metabolism in  mammals58–61. Although further 
in-depth investigations are needed to delineate the mechanisms by which orexin activate ERK1/2 in chicken 
hepatocytes, we speculate that Gq/Gi, PLC, and PKC are potentially  involved54,62.
In conclusion, this is the first report evidencing the hepatic expression of orexin system in avian (non-
mammalian) species and its role in lipogenesis via ERK1/2 pathway. This is significant because it identified a new 
molecular signature that could open new vistas for mechanistic understanding of avian hepatic lipid metabolism.
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